Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Structurally the termini of FGF are
2022-01-03

Structurally, the termini of FGF21 are critical for effective signaling. Progressive amino telomerase inhibitor truncation at either end of the protein sequentially impairs FGF21 bioactivity, but via different mechanisms. Shortening at the N-terminus weakens its ability to activate the FGFR/KLB-com
-
Plasmid construction and site directed mutagenesis of
2022-01-03

Plasmid construction and site-directed mutagenesis of M. luteus B-P 26 UPS. For the expression of N-terminus His6-tagged M. luteus B-P 26 UPS, the expression plasmid pMluUEX [7] was cleaved with the restriction enzymes NdeI/BamHI. The gene fragment was inserted into an NdeI/BamHI-treated pET-15b to
-
Hyperhomocysteinemia HHcy is a clinical condition characteri
2022-01-03

Hyperhomocysteinemia (HHcy) is a clinical condition characterized by increased levels of plasma homocysteine (Hcy) and a well-known risk factor for CVDs. Hcy is a sulfur-containing non-protein amino lysophosphatidic acid australia formed during the intracellular conversion of methionine to cysteine.
-
One of the possibilities of HO targeting
2022-01-03

One of the possibilities of HO-1 targeting is gene therapy. So far, the majority of preclinical studies have focused on recombinant adeno-associated viral (rAAV) vectors as DNA carriers. They not only provide stable, long-term transgene expression in non-dividing flavin adenine dinucleotide australi
7939 records 530/530 page Previous First page 上5页 526527528529530